Skip to content

Study · In vitro (cells) · xenopus · 1990

3 results

Thymosins: both nuclear and cytoplasmic proteins.

Watts JD, Cary PD, Sautiere P, Crane-Robinson C

European journal of biochemistry1 Sept 1990Cited by 56 (Europe PMC)

PMID2209614 (opens in a new tab)DOI10.1111/j.1432-1033.1990.tb19271.x (opens in a new tab)PepBankPUB-02209614
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In Xenopus oocytes, injected calf thymosin beta‑4 remained in the cytoplasm, whereas human prothymosin alpha and rat parathymosin migrated to the nucleus.

    In plain wordsIn frog egg cells, thymosin beta‑4 stayed in the cytoplasm, while two related proteins moved into the nucleus.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableCellular location after injection
    Study

    Xenopusn: not reported in source

    Xenopus oocytes
    Comparator
    Prothymosin alpha and parathymosin
    Outcome group
    Receptor activity and mechanism · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It is shown that human prothymosin alpha and rat parathymosin both migrate to the nucleus whilst thymosin beta 4 remains in the cytoplasm.
    1 context sentence
    Summary · context
    The cellular locations of human prothymosin alpha, rat parathymosin and calf thymosin beta 4, all so-called 'thymic hormones', have been studied by injection into the cytoplasm of Xenopus oocytes, followed by separate monitoring of nuclear and cytoplasmic concentrations.

Studies that did not test the peptide alone2

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Other

    A perchloric acid extraction procedure prepared and purified bovine thymosin beta‑4, together with prothymosin alpha and thymosin beta 9, in high yields.

    In plain wordsIn lab work, a simple extraction method gave high yields of purified thymosin beta‑4 and two related proteins.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicablePerchloric acid extraction and purification yield
    Study

    bovinen: not reported in source

    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    A simple procedure based on perchloric acid extraction has been developed for the preparation and purification of bovine prothymosin alpha and thymosins beta 4 and beta 9 in high yields.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Other

    Spectroscopic observations showed that thymosin beta‑4 and the other proteins studied are non-folding at neutral pH.

    In plain wordsIn lab tests, thymosin beta‑4 and two related proteins did not fold into a fixed shape at neutral pH.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableFolding state at neutral pH
    Study

    n: not reported in source

    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    Spectroscopic observations show these proteins to be non-folding at neural pH.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.